ArticleTranslational lung cancer research2026
Highest mediastinal lymph node metastasis was not an independent prognostic factor in pathological stage N2 non-small cell lung cancer.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Based on the definition of R stage proposed by the International Association for the Study of Lung Cancer (IASLC), non-small cell lung cancer (NSCLC) patients with highest mediastinal lymph node (HMLN) metastasis should be classified as uncertain resection. However, previous studies about HMLN metastasis had different voices, and the prognostic significance of HMLN metastasis is still controversial. This study aimed to investigate the impact of HMLN metastasis on overall survival (OS) and disease-free survival (DFS) in patients with pathological stage N2 (pN2) NSCLC. Methods: Patients with pN2 NSCLC treated between 2001 and 2014 were retrospectively included, while those with R1/R2 resection or insufficient lymph node dissection were excluded. Patients were categorized into two groups: those with HMLN metastasis (HMLN Results: The study included 332 patients, of whom 142 (42.8%) had HMLN metastasis. After PSM, 90 matched pairs were generated. Patients in the HMLN Conclusions: HMLN metastasis was not an independent prognostic factor for OS or DFS in patients with stage N2 NSCLC. Patients with HMLN metastasis were more likely to have pN2b disease, which may account for the poorer survival observed in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.